Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. more
Time Frame | VRPX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 20.12% | -2.27% | -0.57% |
1-Month Return | -35.48% | -3.96% | 1.21% |
3-Month Return | -51.69% | -9.7% | 7.57% |
6-Month Return | -43.18% | -3.37% | 11.45% |
1-Year Return | -89.25% | 3.71% | 28.48% |
3-Year Return | -98.99% | 3.8% | 29.52% |
5-Year Return | -99.39% | 39.78% | 90.66% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 3.18M | 4.20M | 12.03M | 21.85M | 15.19M | [{"date":"2019-12-31","value":14.57,"profit":true},{"date":"2020-12-31","value":19.21,"profit":true},{"date":"2021-12-31","value":55.05,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":69.53,"profit":true}] |
Operating Income | (3.18M) | (4.20M) | (12.03M) | (21.85M) | (12.94M) | [{"date":"2019-12-31","value":-318186800,"profit":false},{"date":"2020-12-31","value":-419571900,"profit":false},{"date":"2021-12-31","value":-1202550000,"profit":false},{"date":"2022-12-31","value":-2184513300,"profit":false},{"date":"2023-12-31","value":-1293978800,"profit":false}] |
Total Non-Operating Income/Expense | (249.29K) | (291.87K) | (123.39K) | 195.23K | - | [{"date":"2019-12-31","value":-127.69,"profit":false},{"date":"2020-12-31","value":-149.5,"profit":false},{"date":"2021-12-31","value":-63.2,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (3.31M) | (4.34M) | (12.06M) | (21.65M) | (15.19M) | [{"date":"2019-12-31","value":-330651200,"profit":false},{"date":"2020-12-31","value":-433965300,"profit":false},{"date":"2021-12-31","value":-1205606300,"profit":false},{"date":"2022-12-31","value":-2165072000,"profit":false},{"date":"2023-12-31","value":-1518950800,"profit":false}] |
Income Taxes | 124.64K | 147.93K | 92.82K | (194.41K) | (12.94K) | [{"date":"2019-12-31","value":84.26,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":62.75,"profit":true},{"date":"2022-12-31","value":-131.42,"profit":false},{"date":"2023-12-31","value":-8.75,"profit":false}] |
Income After Taxes | (3.43M) | (4.49M) | (12.15M) | (21.46M) | - | [{"date":"2019-12-31","value":-343115600,"profit":false},{"date":"2020-12-31","value":-448758700,"profit":false},{"date":"2021-12-31","value":-1214888500,"profit":false},{"date":"2022-12-31","value":-2145630700,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (3.31M) | (4.34M) | (12.06M) | (21.65M) | (13.61M) | [{"date":"2019-12-31","value":-330651200,"profit":false},{"date":"2020-12-31","value":-433965300,"profit":false},{"date":"2021-12-31","value":-1205606300,"profit":false},{"date":"2022-12-31","value":-2165072000,"profit":false},{"date":"2023-12-31","value":-1361491200,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (3.43M) | (4.49M) | (12.15M) | (21.46M) | (15.19M) | [{"date":"2019-12-31","value":-343115600,"profit":false},{"date":"2020-12-31","value":-448758700,"profit":false},{"date":"2021-12-31","value":-1214888500,"profit":false},{"date":"2022-12-31","value":-2145630700,"profit":false},{"date":"2023-12-31","value":-1518950800,"profit":false}] |
EPS (Diluted) | (1.07) | (2.15) | (1.94) | (1.85) | (4.81) | [{"date":"2019-12-31","value":-107.26,"profit":false},{"date":"2020-12-31","value":-215.5,"profit":false},{"date":"2021-12-31","value":-194,"profit":false},{"date":"2022-12-31","value":-185,"profit":false},{"date":"2023-12-31","value":-481,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VRPX | |
---|---|
Cash Ratio | 0.01 |
Current Ratio | 0.13 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VRPX | |
---|---|
ROA (LTM) | -91.42% |
ROE (LTM) | -362.29% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VRPX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 7.75 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -6.75 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VRPX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.48 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Virpax Pharmaceuticals Inc (VRPX) share price today is $0.4
Yes, Indians can buy shares of Virpax Pharmaceuticals Inc (VRPX) on Vested. To buy Virpax Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRPX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Virpax Pharmaceuticals Inc (VRPX) via the Vested app. You can start investing in Virpax Pharmaceuticals Inc (VRPX) with a minimum investment of $1.
You can invest in shares of Virpax Pharmaceuticals Inc (VRPX) via Vested in three simple steps:
The 52-week high price of Virpax Pharmaceuticals Inc (VRPX) is $5.48. The 52-week low price of Virpax Pharmaceuticals Inc (VRPX) is $0.3.
The price-to-earnings (P/E) ratio of Virpax Pharmaceuticals Inc (VRPX) is
The price-to-book (P/B) ratio of Virpax Pharmaceuticals Inc (VRPX) is 0.48
The dividend yield of Virpax Pharmaceuticals Inc (VRPX) is 0.00%
The market capitalization of Virpax Pharmaceuticals Inc (VRPX) is $3.03M
The stock symbol (or ticker) of Virpax Pharmaceuticals Inc is VRPX